Advanced Medical Solutions announces Grahame Cook to its Board as Non-Executive Director

– UK, Winsford –  Advanced Medical Solutions Group plc (LON: AMS), the surgical and advanced wound care specialist company, today announced the appointment of Grahame Cook to its Board as a Non-Executive Director, effective on 1 February 2021.

Steve Bellamy, who has been an AMS Board member since 2007, will retire from the Board at the next AGM.

“I am delighted to welcome Grahame to the Board of AMS. Grahame brings significant financial experience and knowledge of the healthcare sector. His experience of driving significant value creation at a number of healthcare companies will be invaluable in the next stage of AMS’s growth. He will make a valuable contribution to our Board.” said Board Chairman, Peter Allen.

He added: “The Board would like to thank Steve for his significant contribution to the success of AMS over the past fourteen years.”

About Grahame Cook

Grahame has extensive experience as an Executive and Non-Executive Director in a wide range of public and private organizations. He is a chartered accountant and was an investment banker for 18 years, focusing on global equity capital markets, M&A, and corporate advisory. For the past 18 years, he has been a Non-Executive Director, most recently on the Boards of Horizon Discovery plc and Morphogenesis Inc, and Chairman of Sinclair Pharma plc.

Grahame Cook said: “I have known and admired AMS’s business for many years and am proud to be able to join the team. I look forward to working with the Board to execute on its strategy and build on its strong position in the surgical and wound care markets.”

About Advanced Medical Solutions Group plc

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and wound care markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, hemostats, and internal fixation devices, which it markets under its brands LiquiBand, RESORBA, and LiquiBandFix8. AMS also supplies wound care dressings such as silver alginates, alginates, and foams through its ActivHeal brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France. In 2020, the Group acquired Raleigh Adhesive Coatings, a leading coater and converter of materials predominately for wound care and bio-diagnostics products based in the UK.

AMS’s products, manufactured in the UK, Germany, France, Israel, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic, and Russia. The Group has R&D innovation hubs in the UK, Germany, France, and Israel. Established in 1991, the Group has more than 700 employees.

For more information: https://www.admedsol.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.